Chronic Pain and Cannabis: Why Daily Function Matters

What counts as progress for someone living with chronic pain? A lower pain score matters. So does being able to prepare dinner, finish a workday, or spend time with family without symptoms taking over. These outcomes overlap, but they are not interchangeable.

A new study, “Sense of coherence and health-related outcomes in medical cannabis patients with chronic pain,” examines that distinction through the experiences of 156 Brazilian patients.¹ Accepted for publication in the Journal of Psychiatric Research, it explores how patients’ sense that life is understandable, manageable, and meaningful relates to their health.

The findings point toward a broader way of evaluating cannabis care. Patients with stronger psychological resources reported better outcomes across several measures, particularly depression and pain’s interference with daily life. The opportunity is to understand the whole patient more clearly, while recognizing that this study cannot establish whether cannabis produced those differences.

What Is Sense of Coherence?

“Sense of coherence,” abbreviated SOC, describes how people perceive and navigate life’s demands. It has three components: comprehensibility, manageability, and meaningfulness.

Comprehensibility means events feel sufficiently understandable rather than entirely unpredictable. Manageability concerns whether someone believes resources are available to meet challenges. Meaningfulness describes whether those challenges feel worth engaging with.

Consider a hypothetical patient who understands their diagnosis, has reliable support, and wants to regain enough mobility to visit friends. Those circumstances may help make daily life feel more manageable even while pain persists. Another patient with a similar pain score might face confusing information, financial strain, and isolation.

SOC is therefore more specific than “positive thinking.” Nor does studying it imply that pain is imaginary or that people are responsible for their symptoms. The question is how psychological and practical resources relate to living with a real, persistent health condition.

How Researchers Studied Medical Cannabis Patients

Researchers recruited participants through five Brazilian nonprofit cannabis associations. Patients completed an online survey between March 2023 and September 2024. Of 247 people who accessed the survey, 156 met the inclusion criteria.

Participants were aged 18 to 65 and had used cannabis oil supplied by a participating association continuously for at least 30 days. Their average age was approximately 47. Most were white women, and fibromyalgia was the most frequently reported pain condition, affecting 37.1% of the sample.

The survey combined established questionnaires measuring SOC, pain intensity, pain interference, depression, anxiety, stress, sleep, and quality of life.

This was a cross-sectional study: a snapshot of patients’ circumstances. Researchers did not assign cannabis treatments, compare cannabis against a placebo, or measure participants before and after treatment. They investigated which characteristics occurred together.

Pain Interference Reveals a Different Part of the Story

Across the sample, average pain intensity was 3.99 on a zero-to-ten scale, while average pain interference was 4.48. The researchers described these as mild intensity and moderate interference.

That difference is useful. Pain intensity asks how much something hurts. Pain interference asks how much it disrupts activities and other parts of life. A symptom can remain tolerable in isolation while repeatedly interrupting sleep, movement, or social participation.

Stronger SOC was associated with both lower intensity and less interference, but the association with interference was stronger. In the regression model examining the two pain measures together, interference remained significantly associated with SOC, whereas intensity did not.

Researchers also compared patients in the highest and lowest thirds of SOC scores. These exploratory groups contained 51 and 53 participants, respectively. The middle third was excluded from this particular comparison.

Values are group averages from the study’s exploratory comparisons. The questionnaires use different scales, so the size of a depression score should not be compared directly with a pain score. These differences are associations between groups, not improvements attributable to treatment.

Why Better Function Deserves Its Own Measurement

The most useful implication is a measurement question: could cannabis research miss meaningful outcomes when it emphasizes pain intensity alone?

Imagine two patients whose pain falls by the same amount. One resumes cooking and walking with a partner. The other remains unable to complete routine tasks. Their numerical pain changes match, but their experiences do not.

The reverse also matters. Feeling less pain would be a less convincing success if a treatment simultaneously made someone too drowsy to function comfortably. Measuring activity, sleep, mood, and unwanted effects alongside pain gives researchers a more complete account of benefit.

This perspective fits the broader discussion in MyCannabis’s updated overview of cannabis for chronic pain. It also complements recent coverage of cannabinoid formulations across different pain conditions: product composition is one research question, while the outcomes used to judge that product are another.

The Brazilian findings do not establish a better treatment strategy. They show why measuring everyday functioning deserves a central place in future studies.

What This Study Cannot Tell Us About Cannabis

Everyone in the sample was already using medical cannabis. Without a comparable group of nonusers or pretreatment measurements, relatively favorable scores cannot be credited to cannabis.

Direction also remains uncertain. A stronger sense of coherence might help someone navigate persistent symptoms. Less depression or disruption might make life feel more manageable. Both could reflect other influences, including financial security, social support, or access to care.

The online sample further limits generalization. Participants came exclusively from cannabis associations and were predominantly white, female, and relatively well educated. Their experiences may differ from those of patients outside these networks.

Separate treatment evidence provides important context. A 2026 systematic review of cannabis-based products for chronic pain examined 25 short-term randomized trials. Certain THC-containing preparations produced small average reductions in pain, alongside increased dizziness, sedation, and nausea. Results varied by product, and low-THC-to-CBD interventions may not improve outcomes.

Those findings reinforce the value of precise questions. Evidence about one preparation cannot automatically establish the value of another, and an association among cannabis users cannot demonstrate that cannabis caused it.

Support Around Treatment Is a Research Opportunity

The Brazilian study raises another possibility worth testing: care delivery itself may matter alongside the product.

All participants received cannabis through nonprofit associations. Such settings could potentially influence access, information, or patients’ sense of support. However, the researchers did not isolate these effects, so the study cannot show that association membership improved outcomes.

A useful next step would be to investigate the surrounding support directly. In September 2026, the University of Michigan announced a cannabis coaching feasibility trial for chronic low back pain. The planned study compares personalized coaching with access to educational and tracking resources without coaching.

Its initial purpose is to determine whether the approach can be delivered and studied successfully, rather than establish definitive effectiveness. Nevertheless, it illustrates how research can examine the decisions and support surrounding cannabis use, not only the substances consumed.

Questions That Make Outcomes More Meaningful

For future research and informed conversations about care, the Brazilian findings suggest several useful questions:

• Is pain becoming less disruptive to activities that matter to the patient?
• Are sleep, mood, and daily functioning changing alongside pain intensity?
• What support or barriers might help explain those changes?

These questions should broaden assessment, not turn SOC into a test patients must pass. A low score could identify unmet needs rather than predict that someone will fail treatment.

The Next Step for Medical Cannabis Research

A stronger follow-up study would track patients from before treatment, document cannabinoid exposure and other care, and repeatedly measure pain, functioning, mood, and SOC. An appropriate comparison group would help distinguish treatment-related changes from other influences.

Researchers could then test whether baseline SOC predicts later outcomes, whether it changes as health improves, or whether additional support produces measurable benefits.

The promising message is that chronic pain research can become more attentive to what patients are trying to recover. A lower pain score is valuable. Understanding whether someone can participate more fully in daily life makes that number more meaningful.

References:

¹ Din, S. F. S. E., Santos, H. F., Tucci, A. M., & Ribeiro, A. M. (2026). Sense of coherence and health-related outcomes in medical cannabis patients with chronic pain: A cross-sectional study. Journal of Psychiatric Research. Advance online publication. https://doi.org/10.1016/j.jpsychires.2026.10.030